BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 6, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Heptares Therapeutics identifies new GPR35 agonists
To read the full story,
subscribe
or
sign in
.
Cancer
Heptares Therapeutics identifies new GPR35 agonists
Nov. 16, 2022
No Comments
Heptares Therapeutics Ltd. has presented G protein-coupled receptor GPR35 agonists reported to be useful for the treatment of acute and chronic pain, gastrointestinal and lung diseases.
BioWorld Science
Cancer
Patents